Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

August 6, 2019 at 4:05 PM EDT

BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 6, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that CEO Sandy Macrae will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City. The presentation is scheduled for Wednesday, August 14 at 1:20 p.m. Eastern Time.

The Wedbush presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will also be available on the Sangamo website after the event.

Earlier in the week, Dr. Macrae will participate in the BTIG Biotechnology Conference 2019 in a panel discussion, “Exploring the Novel Approaches to Treating Sickle Cell Disease”. This event is scheduled for Monday, August 12 at 1:00 p.m. Eastern Time. No webcast is available for the BTIG event.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com

Source: Sangamo Therapeutics, Inc.

Investor Relations – Global
McDavid Stilwell
510-970-6000, x219
mstilwell@sangamo.com

Media Inquiries – Global
Aron Feingold
510-970-6000, x421
afeingold@sangamo.com

Investor Relations and Media Inquiries – European Union & United Kingdom
Caroline Courme
33 4 97 21 27 27
ccourme@sangamo.com